Aurora Cannabis Inc (ACB) Stock AnalysisACBStock AnalysisAurora Cannabis Inc

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company operates through its Cannabis segment. The Cannabis segment comprises the Canadian, Europe, Australian and New Zealand CGUs. The Company offers cannabis products including dried flower, pre-rolls, infused pre-rolls, capsules, cannabis oils, concentrates, vapes, edibles, beverages, and topicals. Its brands include Aurora, MedReleaf, Pedanios, San Raf, WMMC, Tasty's, and others. The Company is engaged in distributing wholesale medical cannabis in various international markets, including Australia and New Zealand. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., and ACB Captive Insurance Company Inc., among others. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).

Aurora Cannabis Inc is currently trading at $4.01, which is below Curaleaf's recent acquisition offer of $4 per share, indicating potential undervaluation. However, the stock has a high RSI of 76.68, suggesting it may be overbought in the short term. The company has reported a significant net revenue increase of 11% year-over-year, reaching $231.3 million, but still faces challenges with a forward P/E ratio of 109.89, indicating high expectations for future earnings. The main risk is the recent decline in stock value of approximately 35% over the past year, alongside ongoing operational struggles and inventory impairments.